Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	37.36	40.79	45.79	35.44	11.36	55.74
Short-Term Investments	13.47	14.99	2.02	0.05	46.52	2.62
Cash & Short-Term Investments	50.83	55.78	47.81	35.49	57.88	58.36
Cash Growth	20.20%	16.68%	34.69%	-38.67%	-0.83%	40.41%
Accounts Receivable	0.79	0.89	0.64	0.75	0.3	50.84
Other Current Assets	1.35	2.49	2.55	2.2	1.83	2.35
Total Current Assets	52.97	59.16	51	38.44	60	111.55
Net Property, Plant & Equipment	4.48	4.7	4.4	4.77	5.67	4.87
Other Intangible Assets	31.7	31.7	46.54	46.56	46.69	46.82
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Long-Term Assets	6.4	6.36	0.61	0.58	0.63	0.63
Total Assets	106.22	112.58	113.22	101.02	123.66	174.55

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5.39	7.18	5.44	6.27	8.61	27.97
Current Portion of Leases	0.95	0.85	1.15	0.88	0.95	0.83
Unearned Revenue	1.68	3.33	7.39	10.81	9.42	18.12
Other Current Liabilities	-	-	-	-	-	0.2
Total Current Liabilities	8.02	11.37	13.98	17.96	18.98	47.12
Long-Term Leases	1.35	1.57	1.36	2.07	2.94	1.97
Other Long-Term Liabilities	37.06	56.31	20.87	18.97	29.8	34.56
Total Long-Term Liabilities	38.41	57.87	22.23	21.04	32.75	36.53
Total Liabilities	46.42	69.24	36.21	39	51.73	83.65

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	535.72	515.47	484.72	451.34	440.28	434.53
Accumulated Other Comprehensive Income	-4.47	-3.92	-2.88	-3.07	-3.57	-5.21
Retained Earnings	-470.33	-467	-403.47	-384.86	-363.37	-337.1
Total Common Shareholders' Equity	60.92	44.55	78.38	63.42	73.34	92.22
Minority Interest	-1.12	-1.2	-1.37	-1.4	-1.4	-1.32
Shareholders' Equity	59.8	43.35	77.01	62.02	71.94	90.9
Total Liabilities & Equity	106.22	112.58	113.22	101.02	123.66	174.55

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2.3	2.42	2.51	2.95	3.9	2.8
Net Cash (Debt)	48.53	53.36	45.29	32.54	53.98	55.56
Net Cash Growth	20.92%	17.82%	39.19%	-39.72%	-2.84%	45.21%
Net Cash Per Share	0.20	0.23	0.23	0.19	0.32	0.34
Book Value	60.92	44.55	78.38	63.42	73.34	92.22
Book Value Per Share	0.25	0.19	0.39	0.37	0.43	0.56
Tangible Book Value	18.54	2.18	21.17	6.19	15.98	34.73
Tangible Book Value Per Share	0.08	0.01	0.11	0.04	0.09	0.21

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Aug 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 10, 2026

Data Sources Report a data error